Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 13,774 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Perennial Allergic Rhinitis (PAR)
Interventions: Beclomethasone Dipropionate (BDP) Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 824 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 46
States / cities: Little Rock, Alaska • Phoenix, Arizona • Encinitas, California + 39 more

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Cypress, California • Irvine, California • Los Angeles, California + 10 more

Conditions: Major Depressive Disorder
Interventions: AGO178; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 95
States / cities: Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 81 more

Conditions: Epilepsy Intractable
Interventions: Direct electrical stimulation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more

Conditions: Solid Tumor Malignancy
Interventions: Pemigatinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 44
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more

Conditions: Migraine Disorders
Interventions: ALD403, Placebo; Biological
Lead sponsor: Alder Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 82
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Acute-On-Chronic Liver Failure, Ascites
Interventions: VS-01 on top of SOC, SOC (Control Group); Drug · Other
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Knee Osteoarthritis
Interventions: SM04690, Placebo, Sham; Drug · Other
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 74
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more

Conditions: Constipation-Predominant Irritable Bowel Syndrome
Interventions: Renzapride; Drug
Lead sponsor: Alizyme; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 126
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
Interventions: Ceritinib; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions: Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more

Conditions: Hereditary Angioedema
Interventions: KVD900 600 mg, KVD900 300 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, insulin glargine; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 314
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 252 more

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Liver Transplantation
Interventions: MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more

Conditions: Major Depressive Disorder
Interventions: NSI-189; Drug
Lead sponsor: Neuralstem Inc.; Industry
Eligibility: 18 Years to 61 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Garden Grove, California • National City, California • Denver, Colorado + 9 more

Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions: Trabectedin, Dexamethasone; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 74
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more

Conditions: Multiple Sclerosis
Interventions: AFO; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Achalasia, Esophageal, Esophagogastric Junction Outflow Obstruction, Spastic Esophageal Disorders
Interventions: FLIP Imaging under various standard of care anesthetics in the context of endotracheal intubation.; Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Interventions: Azacitidine, Entinostat, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Annapolis, Maryland + 4 more

Conditions: Asthma
Interventions: Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 12 Years and older
Enrollment: 1,430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Gammagard Liquid and rHuPH20 in PID

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

Memory Retrieval and Encoding Investigated by Neural Stimulation

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

A Multicenter Assessment of ALD403 in Chronic Migraine

Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Allergic Disease Onset Prevention Study

Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Long Term Open Label Continuation Study

Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis

The Impact of Anesthetics on FLIP

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery